ClinicalTrials.gg
CompletedNCT00940498B2151001Updated Nov 2, 2018Results posted

Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

A Phase 1 interventional study of PF-05212384 (also known as PKI-587) in Neoplasms, sponsored by Pfizer. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-11-02.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Phase 1
  • Dose Finding
  • Solid Tumors
  • Tumors
  • PF-05212384
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 78 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic diagnosis of any solid tumor
  • Incurable cancer, with disease progression following at least 1 therapy with no further standard treatment available in the opinion of the investigator.
  • At least 1 evaluable lesion per criteria

Exclusion criteria

Exclusion Criteria:

  • Clinically unstable primary or CNS tumors
  • Subjects with known diabetes
  • greater than 470 ms.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    1

    PF-05212384 (also known as PKI-587)

    Drug: PF-05212384 (also known as PKI-587)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

  2. Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs included both serious and non-serious adverse events.

    Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

  3. Number of Participants With Laboratory Abnormalities

    Criteria for laboratory test abnormality: hematology (hemoglobin \[less than {\<} 0.8\*lower limit of normal {LLN}\], platelets \[\<0.5\*LLN or greater than {\>} 1.75\*upper limit of normal {ULN}\], white blood cells \[\<0.6\*LLN or \>1.5\*ULN\], lymphocytes \[\<0.8\*LLN or \>1.2\*ULN\], total neutrophils \[\<0.8\*LLN or \>1.2\*ULN\], basophils, eosinophils, monocytes \[\>1.2\*ULN\]); coagulation \[partial thromboplastin time, prothrombin (PT), PT international ratio \[\>1.1\*ULN\]); liver function (total bilirubin \[\>1.5\*ULN\], aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase \[\>0.3\*ULN\], total protein, albumin \[\<0.8\*LLN or \>1.2\*ULN\]).

    Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

  4. Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: Grade 3 nonhematologic AE (including nausea, vomiting, or diarrhea despite optimal therapy; or greater than or equal to \[\>=\] grade 3 asthenia \>2 days; or fasting serum glucose \>250 milligrams per deciliter (mg/dL) despite optimal therapy); \>=Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade 4 neutropenia lasting more than 7 days; Febrile neutropenia; other Grade 4 hematologic AE; delay of treatment \>2 consecutive weeks due to toxicity. Grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

    Time frame: Baseline up to Day 28

  5. Recommended Phase-2 Dose (RP2D)

    RP2D of PF-05212384 was determined based on the safety profile including laboratory and clinical assessments and pharmacodynamics findings.

    Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-05212384: Single and Multiple Dose

    Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose

    Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (Clast).

    Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1

  3. Plasma Decay Half-Life (t1/2) of PF-05212384: Single and Multiple Dose

    Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.

    Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose

    AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - inf).

    Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1

  5. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05212384: Single and Multiple Dose

    Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 168 hours (1 Week). For Cycle 2, the last PK sample for parameter calculations was on 120 hours after the Day 1 dose, however AUCtau was extrapolated to 168 hours using t1/2.

    Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1

  6. Number of Participants With Maximum Increase From Baseline in Corrected QT Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of Participants with maximum increase from baseline in QTcB and QTcF of \< 30 msec, between \<=30 to \<60 msec and \>=60 were reported.

    Time frame: Baseline up to Cycle 14 (each cycle is 28 days)

  7. Change From Baseline in Serum Glucose at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment

    Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)

  8. Change From Baseline in Serum Insulin at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment

    Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)

  9. Change From Baseline in Serum C-peptide at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment

    Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)

  10. Change From Baseline in Hair Follicle Biopsy Biomarkers at Cycle 1 Day 1

    Analysis of hair follicles was conducted using a Reverse Phase Microarrays (RPMA) assay. Phosphoprotein biomarkers measured were pAkt S473, pAkt T308, pStat3 (Y705), Ki-67, and pPRAS40 (T246).

    Time frame: Baseline, 2, 3 and 72 hours (H) postdose on Day 1 of Cycle 1

  11. Change From Baseline in Fresh Tumor Biopsy Biomarkers at Cycle 1 Day 22

    Tumor biopsies were taken from participants of reporting arm PF-05212384 154 mg dose level at baseline and at Cycle 1/Day 22. Biopsies were fixed in optimal cutting temperature compound and analyzed via RPMA. The biomarkers tested were phosphorylated versions of the proteins: AKT S473, AKT T308, FKHR T24 / FKHR1 T32, and STAT3. This outcome measure was planned to be analyzed only for the reporting arm Part 1 and 2: PF-05212384 154 mg, as pre-specified in protocol.

    Time frame: Baseline, Day 22 of Cycle 1

  12. Number of Participants With Mutation, Deletion, Amplification in Phosphatidylinositol 3-kinase (PI3K) Pathway Signaling Related Genes and/or Proteins in Biopsied Tumor Tissue

    Biopsied tumor tissue was analyzed for alterations in the phosphoinositide-3-kinase/rat sarcoma (PI3K/RAS) signaling pathway by molecular approaches. The biomarkers studied were PIK3CA and phosphatase and tensin homolog (PTEN) by immunohistochemistry.

    Time frame: Baseline

  13. Percentage of Participants With Objective Response (OR)

    Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters). Percentage of participants with objective response were reported.

    Time frame: Baseline until disease progression or death due to any cause (up to Cycle 14 [each cycle 28 days])

07

Results

Posted Nov 2, 2018

Participant flow

Participant flow — Overall Study
MilestonePart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Started444443784
Completed131234673
Not completed31329111
Withdrew: Death20015010
Withdrew: Lost to follow-up11201001
Withdrew: Disease progression00110100
Withdrew: Physician decision00002000
Withdrew: Not treated due to disease related pain00001000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Time frame:
Baseline up to Cycle 14 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
ParticipantsPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
AEs444442784
SAEs211116052
PrimaryNumber of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs included both serious and non-serious adverse events.

Time frame:
Baseline up to Cycle 14 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)
ParticipantsPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
AEs334440784
SAEs00001002
PrimaryNumber of Participants With Laboratory Abnormalities

Criteria for laboratory test abnormality: hematology (hemoglobin \[less than {\<} 0.8\*lower limit of normal {LLN}\], platelets \[\<0.5\*LLN or greater than {\>} 1.75\*upper limit of normal {ULN}\], white blood cells \[\<0.6\*LLN or \>1.5\*ULN\], lymphocytes \[\<0.8\*LLN or \>1.2\*ULN\], total neutrophils \[\<0.8\*LLN or \>1.2\*ULN\], basophils, eosinophils, monocytes \[\>1.2\*ULN\]); coagulation \[partial thromboplastin time, prothrombin (PT), PT international ratio \[\>1.1\*ULN\]); liver function (total bilirubin \[\>1.5\*ULN\], aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase \[\>0.3\*ULN\], total protein, albumin \[\<0.8\*LLN or \>1.2\*ULN\]).

Time frame:
Baseline up to Cycle 14 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Number of Participants With Laboratory Abnormalities434341774
PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: Grade 3 nonhematologic AE (including nausea, vomiting, or diarrhea despite optimal therapy; or greater than or equal to \[\>=\] grade 3 asthenia \>2 days; or fasting serum glucose \>250 milligrams per deciliter (mg/dL) despite optimal therapy); \>=Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade 4 neutropenia lasting more than 7 days; Febrile neutropenia; other Grade 4 hematologic AE; delay of treatment \>2 consecutive weeks due to toxicity. Grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Time frame:
Baseline up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Number of Participants With Dose Limiting Toxicities (DLTs)00002532
PrimaryRecommended Phase-2 Dose (RP2D)

RP2D of PF-05212384 was determined based on the safety profile including laboratory and clinical assessments and pharmacodynamics findings.

Time frame:
Baseline up to Cycle 14 (each cycle is 28 days)
Reported as:
Number · mg
Recommended Phase-2 Dose (RP2D)
mgPF-05212384 : All Participants
Recommended Phase-2 Dose (RP2D)154
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-05212384: Single and Multiple Dose
Time frame:
Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of PF-05212384: Single and Multiple Dose
nanogram per milliliter (ng/mL)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Cycle 1714.1 ± 331674 ± 103317 ± 106508 ± 1069988 ± 2814730 ± 5414240 ± 2927090 ± 26
Cycle 2542.8 ± 281482 ± 242601 ± 334250 ± 438594 ± 6415660 ± 8610840 ± 46NA ± NA
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose

Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (Clast).

Time frame:
Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter(ng*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose
nanogram*hour per milliliter(ng*hr/mL)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose1149 ± 352367 ± 245741 ± 1413090 ± 7715780 ± 2826550 ± 3028180 ± 3646760 ± 2
SecondaryPlasma Decay Half-Life (t1/2) of PF-05212384: Single and Multiple Dose

Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.

Time frame:
Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Reported as:
Mean · hours (hr)
Plasma Decay Half-Life (t1/2) of PF-05212384: Single and Multiple Dose
hours (hr)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Cycle 115.14 ± 6.147517.34 ± 9.868340.73 ± 7.782235.95 ± 9.126735.84 ± 6.245433.33 ± 4.814437.51 ± 4.851638.53 ± 4.5457
Cycle 2—NA ± NANA ± NA37.10 ± 4.423835.97 ± 5.319734.03 ± 6.638536.38 ± 5.1188NA ± NA
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose

AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - inf).

Time frame:
Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose
ng*hr/mLPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose1238 ± 322485 ± 235881 ± 1413280 ± 7816250 ± 2827210 ± 3328280 ± 3947460 ± 2
SecondaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05212384: Single and Multiple Dose

Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 168 hours (1 Week). For Cycle 2, the last PK sample for parameter calculations was on 120 hours after the Day 1 dose, however AUCtau was extrapolated to 168 hours using t1/2.

Time frame:
Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05212384: Single and Multiple Dose
ng*hr/mLPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Cycle 11256 ± 292604 ± 225753 ± 1313100 ± 7815810 ± 2826740 ± 3028220 ± 3646730 ± 2
Cycle 22991 ± 26NA ± NA15820 ± 2925010 ± 4947130 ± 5479380 ± 6461910 ± 42NA ± NA
SecondaryNumber of Participants With Maximum Increase From Baseline in Corrected QT Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of Participants with maximum increase from baseline in QTcB and QTcF of \< 30 msec, between \<=30 to \<60 msec and \>=60 were reported.

Time frame:
Baseline up to Cycle 14 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Increase From Baseline in Corrected QT Interval
ParticipantsPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
QTcB: Change <30333326644
QTcB: <= 30 and <60111013130
QTcB: Change >=6000003010
QTcF: Change <30334334664
QTcF: <= 30 and <6011007120
QTcF: Change >=6000001000
SecondaryChange From Baseline in Serum Glucose at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame:
Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Serum Glucose at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
milligram per deciliter (mg/dL)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Baseline100.3 ± 14.15103.1 ± 14.5587.0 ± 6.2291.1 ± 7.4095.6 ± 13.4896.7 ± 10.8588.4 ± 18.1493.3 ± 3.06
Change at Cycle 1 Day 212.5 ± 29.59-4.0 ± 7.070.3 ± 10.6013.5 ± 4.0813.7 ± 21.4921.1 ± 24.9765.5 ± 41.4154.5 ± 94.71
Change at Cycle 2 Day 11.0 ± 18.3628.4 ± 26.9011.5 ± 7.593.0 ± 9.562.8 ± 15.745.0 ± 6.6712.9 ± 14.459.5 ± 3.54
Change at Cycle 3 Day 119.0 ± NA19.0 ± NA2.0 ± NA9.3 ± 4.6810.4 ± 29.0216.0 ± 15.5626.9 ± 33.77-11.0 ± 1.41
Change at Cycle 4 Day 1-1.0 ± NA7.0 ± NA0.0 ± NA3.6 ± 7.642.0 ± 10.8126.0 ± NA41.6 ± 45.856.5 ± 0.71
Change at Cycle 5 Day 1-9.0 ± NA8.0 ± NA—8.2 ± 8.78-3.8 ± 9.39-3.0 ± NA29.7 ± 33.08-7.0 ± 2.83
Change at Cycle 6 Day 1-7.0 ± NA2.0 ± NA—1.0 ± 1.41-10.0 ± 8.6614.0 ± NA29.1 ± 28.175.0 ± 5.66
Change at Cycle 7 Day 1-9.0 ± NA10.0 ± NA—8.0 ± NA-5.0 ± 2.83—48.7 ± 50.137.0 ± NA
Change at Cycle 8 Day 1-12.0 ± NA6.0 ± NA—11.0 ± NA1.5 ± 21.92—39.0 ± 32.70-3.0 ± NA
Change at Cycle 9 Day 1-7.0 ± NA9.0 ± NA—5.0 ± NA——65.0 ± 42.661.0 ± NA
Change at Cycle 10 Day 1-2.0 ± NA15.0 ± NA—————11.0 ± NA
Change at Cycle 11 Day 1-8.0 ± NA-15.0 ± NA————39.6 ± NA—
Change at Cycle 12 Day 1-9.0 ± NA—————28.8 ± NA—
Change at Cycle 13 Day 1——————-1.8 ± NA—
Change at Cycle 14 Day 1——————36.0 ± NA—
Change at EOT10.7 ± 34.127.2 ± 12.6423.3 ± 31.4816.1 ± 15.077.4 ± 21.08-6.7 ± 13.5227.5 ± 32.7542.0 ± 72.12
SecondaryChange From Baseline in Serum Insulin at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame:
Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Reported as:
Mean · microunits per milliliter (mcU/mL)
Change From Baseline in Serum Insulin at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
microunits per milliliter (mcU/mL)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Baseline ( n=4,1,3,2,35,4,4,3)23.8 ± 22.9010.2 ± NA8.6 ± 4.405.3 ± 1.8413.1 ± 9.3418.2 ± 14.145.9 ± 7.8611.4 ± 7.00
Change at Cycle 1 Day 2 (n =4,1,3,2,37,6,7,4)4.0 ± 33.562.5 ± NA2.9 ± 6.814.7 ± 2.9022.8 ± 25.6840.9 ± 47.0557.5 ± 41.66110.3 ± 117.23
Change at Cycle 2 Day 1 (n =0,0,0,2,27,5,3,1)———5.4 ± 3.541.3 ± 8.662.6 ± 7.887.3 ± 10.31-2.9 ± NA
Change at Cycle 3 Day 1 (n =0,1,1,1,14,1,3,1)—1.4 ± NA2.1 ± NA0.9 ± NA-0.7 ± 11.664.2 ± NA2.1 ± 4.3818.0 ± NA
Change at Cycle 4 Day 1 (n =0,0,1,1,8,0,3,2)——3.1 ± NA3.0 ± NA2.9 ± 6.35—4.2 ± 2.540.6 ± 3.32
Change at Cycle 5 Day 1 (n =0,1,0,1,5,0,3,1)—-0.7 ± NA—0.1 ± NA2.3 ± 5.24—3.3 ± 1.86-3.0 ± NA
Change at C6D1 (n=0,1,0,1,3,0,2,2)—-1.2 ± NA—3.1 ± NA0.9 ± 5.14—0.8 ± 0.070.3 ± 0.42
Change at Cycle 7 Day 1 (n=0,1,0,1,2,0,3,1)—0.9 ± NA—0.2 ± NA2.1 ± 0.85—6.9 ± 8.315.0 ± NA
Change at Cycle 8 Day 1 (n =0,1,0,1,2,0,3,1)—-1.9 ± NA—3.1 ± NA4.5 ± 4.17—-0.9 ± 2.71-1.4 ± NA
Change at Cycle 9 Day 1 ( n=0,1,0,1,0,0,2,1)—5.0 ± NA—0.9 ± NA——1.8 ± 4.60-1.7 ± NA
Change at Cycle 10 Day 1 (n =1,1,0,0,0,0,0,1)-18.3 ± NA3.4 ± NA—————5.8 ± NA
Change at Cycle 11 Day 1 (n =1,1,0,0,0,0,1,0)-32.2 ± NA0.1 ± NA————38.6 ± NA—
Change at Cycle 12 Day 1 (n =1,0,0,0,0,0,0,0)-4.3 ± NA———————
Change at Cycle 13 D 1 (n =0,0,0,0,0,0,1,0)——————22.0 ± NA—
Change at Cycle 14 Day 1 (n =0,0,0,0,0,0,1,0)——————107.0 ± NA—
Change at EOT (n =1,0,1,1,21,4,6,1)19.1 ± NA—0.0 ± NA0.8 ± NA1.7 ± 8.59-4.8 ± 9.0419.6 ± 21.67-4.3 ± NA
SecondaryChange From Baseline in Serum C-peptide at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame:
Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Reported as:
Mean · ng/mL
Change From Baseline in Serum C-peptide at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
ng/mLPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mg
Baseline3.0 ± 1.823.0 ± 1.194.6 ± 1.92
Change at Cycle 1 Day 23.6 ± 2.236.2 ± 4.235.0 ± 5.37
Change at Cycle 2 Day 10.4 ± 1.361.0 ± 1.30-1.1 ± 2.23
Change at Cycle 3 Day 10.5 ± 1.152.5 ± NA-1.8 ± 3.11
Change at Cycle 4 Day 10.9 ± 1.45—0.1 ± 1.56
Change at Cycle 5 Day 10.4 ± 0.86—-1.2 ± 2.87
Change at Cycle 6 Day 1-0.0 ± 0.54—-0.3 ± 1.60
Change at Cycle 7 Day 10.1 ± 0.36—1.9 ± 1.20
Change at Cycle 8 Day 10.3 ± 0.14—-0.9 ± 3.75
Change at Cycle 9 Day 1——2.9 ± NA
Change at EOT1.1 ± 1.82-0.1 ± 0.805.3 ± 1.68
SecondaryChange From Baseline in Hair Follicle Biopsy Biomarkers at Cycle 1 Day 1

Analysis of hair follicles was conducted using a Reverse Phase Microarrays (RPMA) assay. Phosphoprotein biomarkers measured were pAkt S473, pAkt T308, pStat3 (Y705), Ki-67, and pPRAS40 (T246).

Time frame:
Baseline, 2, 3 and 72 hours (H) postdose on Day 1 of Cycle 1
Reported as:
Mean · normalized fluorescence units (NFU)
Change From Baseline in Hair Follicle Biopsy Biomarkers at Cycle 1 Day 1
normalized fluorescence units (NFU)Part 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mg
Baseline: pAkt S47312.2 ± 4.5817.2 ± 5.26—
Baseline: pAkt T30844.3 ± 19.4136.2 ± 15.95—
Baseline: pStat3 (Y705)172.3 ± 47.26224.2 ± 117.43—
Baseline: Ki-6782.1 ± 21.79128.1 ± 30.80145.7 ± NA
Baseline: pPRAS40 (T246)111.7 ± 31.7599.6 ± 30.11—
Change at C1D1 2H:pAkt S473-1.7 ± 3.596.8 ± 5.77—
Change at C1D1 2H:pAkt T3082.3 ± 17.06-4.6 ± NA—
Change at C1D1 2H:pStat3 (Y705)-6.2 ± 34.78126.3 ± NA—
Change at C1D1 2H:Ki-671.0 ± 29.4134.7 ± NA-36.2 ± NA
Change at C1D1 2H:pPRAS40-T246-27.4 ± 22.5942.0 ± 26.01—
Change at C1D1 3hr: pAkt S473-0.9 ± 2.930.2 ± 9.26—
Change at C1D1 3hr: pAkt T3080.4 ± 14.256.9 ± 18.50—
Change at C1D1 3H: pStat3 (Y705)-11.7 ± 54.88-142.2 ± NA—
Change at C1D1 3hr: Ki-67-8.5 ± 23.5925.2 ± 15.68—
Change at C1D1 3H:pPRAS40-T246-27.8 ± 27.1149.8 ± 56.37—
Change at C1D4 72H:pAkt S473-0.9 ± 3.691.7 ± 9.45—
Change at C1D4 72H:pAkt-T3089.4 ± 38.1911.8 ± 15.16—
Change at C1D4 72H: pStat3 (Y705)1.9 ± 35.99239.8 ± NA—
Change at C1D4 72hr: Ki-675.7 ± 38.5913.5 ± 57.80—
Change atC1D4-72H:pPRAS40 T246-2.1 ± 31.5535.6 ± 77.10—
SecondaryChange From Baseline in Fresh Tumor Biopsy Biomarkers at Cycle 1 Day 22

Tumor biopsies were taken from participants of reporting arm PF-05212384 154 mg dose level at baseline and at Cycle 1/Day 22. Biopsies were fixed in optimal cutting temperature compound and analyzed via RPMA. The biomarkers tested were phosphorylated versions of the proteins: AKT S473, AKT T308, FKHR T24 / FKHR1 T32, and STAT3. This outcome measure was planned to be analyzed only for the reporting arm Part 1 and 2: PF-05212384 154 mg, as pre-specified in protocol.

Time frame:
Baseline, Day 22 of Cycle 1
Reported as:
Mean · normalized to cytokeratin (NFC)
Change From Baseline in Fresh Tumor Biopsy Biomarkers at Cycle 1 Day 22
normalized to cytokeratin (NFC)Part 1 and 2: PF-05212384 154 mg
Baseline: AKT S47334.3 ± 26.82
Baseline: AKT T30838.5 ± 25.80
Baseline: FKHR T24 / FKHR1 T32145.1 ± 113.99
Baseline: STAT3231.4 ± 219.22
Change at C1D22: AKT S473-12.3 ± 36.88
Change at C1D22: AKT T308-5.8 ± 25.42
Change at C1D22: FKHR T24 / FKHR1 T32-27.0 ± 82.92
Change at C1D22: STAT3-45.6 ± 139.67
SecondaryNumber of Participants With Mutation, Deletion, Amplification in Phosphatidylinositol 3-kinase (PI3K) Pathway Signaling Related Genes and/or Proteins in Biopsied Tumor Tissue

Biopsied tumor tissue was analyzed for alterations in the phosphoinositide-3-kinase/rat sarcoma (PI3K/RAS) signaling pathway by molecular approaches. The biomarkers studied were PIK3CA and phosphatase and tensin homolog (PTEN) by immunohistochemistry.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Mutation, Deletion, Amplification in Phosphatidylinositol 3-kinase (PI3K) Pathway Signaling Related Genes and/or Proteins in Biopsied Tumor Tissue
ParticipantsPF-05212384 : All Participants
PTEN Mutation: PresentNA
PTEN Mutation: AbsentNA
PTEN Deletion: Present28
PTEN Deletion: Absent28
PTEN Amplification: PresentNA
PTEN Amplification: AbsentNA
PIK3CA Mutation: Present4
PIK3CA Mutation: Absent27
PIK3CA Deletion: PresentNA
PIK3CA Deletion: AbsentNA
PIK3CA Amplification: Present2
PIK3CA Amplification: Absent56
SecondaryPercentage of Participants With Objective Response (OR)

Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters). Percentage of participants with objective response were reported.

Time frame:
Baseline until disease progression or death due to any cause (up to Cycle 14 [each cycle 28 days])
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsPF-05212384 : All Participants
Percentage of Participants With Objective Response (OR)2.6 (0.3 to 9.1)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: PF-05212384 10 mg—2/4 (50%)4/4 (100%)
Part 1: PF-05212384 21 mg—1/4 (25%)4/4 (100%)
Part 1: PF-05212384 43 mg—1/4 (25%)4/4 (100%)
Part 1: PF-05212384 89 mg—1/4 (25%)4/4 (100%)
Part 1 and 2: PF-05212384 154 mg—16/42 (38.1%)42/42 (100%)
Part 1: PF-05212384 222 mg—0/7 (0%)7/7 (100%)
Part 1: PF-05212384 266 mg—5/8 (62.5%)8/8 (100%)
Part 1: PF-05212384 319 mg—2/4 (50%)4/4 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
Disease progressionGeneral disorders2/40/40/40/43/420/71/80/4
Abdominal painGastrointestinal disorders1/40/40/40/41/420/70/81/4
DiarrhoeaGastrointestinal disorders0/40/40/40/40/420/70/81/4
VomitingGastrointestinal disorders0/40/40/40/40/420/70/81/4
Mucosal inflammationGeneral disorders0/40/40/40/41/420/70/81/4
PneumoniaInfections and infestations0/40/40/41/40/420/71/80/4
Respiratory tract infectionInfections and infestations0/41/40/40/40/420/71/80/4
Septic shockInfections and infestations0/40/40/41/40/420/70/80/4
Humerus fractureInjury, poisoning and procedural complications0/40/41/40/40/420/70/80/4
Back painMusculoskeletal and connective tissue disorders0/40/40/40/40/420/70/81/4
Most frequent other events
Showing 10 of 275
Most frequent other events
EventPart 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mg
NauseaGastrointestinal disorders3/42/42/41/422/423/76/83/4
VomitingGastrointestinal disorders3/41/40/40/415/422/75/81/4
FatigueGeneral disorders3/42/42/40/410/423/73/82/4
Mucosal inflammationGeneral disorders0/41/41/40/419/425/76/83/4
Blood alkaline phosphatase increasedInvestigations3/40/41/40/46/420/70/80/4
HyperglycaemiaMetabolism and nutrition disorders1/40/41/40/412/421/74/83/4
RashSkin and subcutaneous tissue disorders0/40/41/43/46/420/76/82/4
AnaemiaBlood and lymphatic system disorders0/41/41/41/46/421/72/82/4
LymphopeniaBlood and lymphatic system disorders0/40/41/40/44/420/70/82/4
DiarrhoeaGastrointestinal disorders1/41/40/42/49/422/72/82/4

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mgTotal
<=18 years000000000
Between 18 and 65 years43443447464
>=65 years0100831013
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PF-05212384 10 mgPart 1: PF-05212384 21 mgPart 1: PF-05212384 43 mgPart 1: PF-05212384 89 mgPart 1 and 2: PF-05212384 154 mgPart 1: PF-05212384 222 mgPart 1: PF-05212384 266 mgPart 1: PF-05212384 319 mgTotal
Female13122054440
Male31322224037
08

Study locations

9 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Insitute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10022, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute, Tennessee Oncology, PLLC
    Nashville, Tennessee 37203-1632, United States
  • Hospital General Vall D'Hebron
    Barcelona, 08035, Spain
  • King's College London
    London, England SE1 9RT, United Kingdom
09

References and documents

Publications

  • Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Brana I, Tabernero J. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. doi: 10.1158/1078-0432.CCR-14-1306. Epub 2015 Feb 4. PubMed 25652454 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2010 to primary completion in Aug 2011, 19 months.

Results were first posted in Nov 2018, 7 years 3 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 19 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2009
First posted
Jul 16, 2009
StartActual
Jan 2010
Primary completionActual
Aug 2011
CompletionActual
Oct 2012
Results first posted
Nov 2, 2018
Last update
Nov 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00940498
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 16, 2009
Start date
Jan 2010
Primary completion
Aug 2011
Completion
Oct 2012
Results posted
Nov 2, 2018
Last update
Nov 2, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gedatolisib

Start the discussion